Cipla (CIPLA) Share Price Falls 2.16% Today as Stock Slips to Rs 1,350.25
- September 11, 2026
- Posted by: Harsh Piplani
- Category: News
Cipla Share Price was at Rs 1,350.25 on 11 September 2026 at 9:52:59 AM IST, down Rs 29.75 or 2.16% for the day, taking the Large Cap pharmaceutical company’s market capitalisation to Rs 1,10,515.04 crore. The stock is in focus because the decline appeared early in the session and kept the price close to the day’s low.
The supplied data confirms the price event, but it does not establish a company-specific catalyst for why the stock is falling today. What the numbers do show is a clear intraday decline from the previous close of Rs 1,380, with the stock opening at Rs 1,370.05, touching the same Rs 1,370.05 as the day’s high, and then slipping to Rs 1,348.95. That pattern indicates weakness from the opening print rather than a late-session swing.
For investors tracking the stock, the broader context is valuation and profitability. Cipla trades at a P/E ratio of 33.08 and a P/B ratio of 3.17, while return ratios stand at ROE of 11.83% and ROCE of 16%. EPS is Rs 41.72, book value per share is Rs 435.18 and dividend yield is 0.94%.
Cipla (CIPLA) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,350.25 |
| Previous Close | Rs 1,380 |
| Today's Move | -Rs 29.75 (-2.16%) |
| Open | Rs 1,370.05 |
| High | Rs 1,370.05 |
| Low | Rs 1,348.95 |
| Turnover | Rs 0.57 crore |
| Market Capitalisation | Rs 1,10,515.04 crore |
| Market Cap Category | Large Cap |
Cipla Share Price Today reflects a weak opening-to-low structure, with the stock failing to move above its opening level and staying under the previous close through the morning session. Turnover stood at Rs 0.57 crore.
In absolute terms, the stock fell Rs 29.75 from Rs 1,380 to Rs 1,350.25. The session began at Rs 1,370.05, which was also the day’s high, and the price later eased to a low of Rs 1,348.95. When a stock opens below the previous close, fails to recover above the opening mark, and trades near the low, it usually signals a soft intraday tone.
Because Cipla is a Large Cap stock with a market cap of Rs 1,10,515.04 crore, even a 2.16% move attracts attention. The verified takeaway is straightforward: the stock weakened early, remained below Rs 1,380, and stayed close to the lower end of the day’s range.
Cipla (CIPLA) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 1,10,515.04 crore |
| P/E Ratio | 33.08x |
| P/B Ratio | 3.17x |
| ROE | 11.83% |
| ROCE | 16% |
| EPS | Rs 41.72 |
| Book Value Per Share | Rs 435.18 |
| Dividend Yield | 0.94% |
Cipla’s fundamentals place it among the larger names in Healthcare and Pharmaceuticals & Drugs, while valuation and return ratios look broadly near industry norms rather than at an extreme.
At a market capitalisation of Rs 1,10,515.04 crore, Cipla remains one of the larger names in its space. The stock trades at a P/E ratio of 33.08 and a P/B ratio of 3.17. EPS stands at Rs 41.72, book value per share is Rs 435.18 and dividend yield is 0.94%.
Profitability metrics are steady but not the strongest within the peer group. ROE is 11.83%, exactly in line with the industry median of 11.83% and slightly above the industry average of 11.22%. ROCE of 16% is stronger than the industry median of 13.68% and average of 13.71%, suggesting better-than-typical capital efficiency for the broader group.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 33.08x |
| Benchmark Median P/E | 32.73x |
| Benchmark Average P/E | 49.1x |
| Benchmark P/E Range | 3.4x to 701.57x |
| Company P/B Ratio | 3.17x |
| Benchmark Median P/B | 3.06x |
| Benchmark Average P/B | 4.42x |
| Company ROE | 11.83% |
| Benchmark Median ROE | 11.83% |
| Benchmark Average ROE | 11.22% |
| Company ROCE | 16% |
| Benchmark Median ROCE | 13.68% |
| Benchmark Average ROCE | 13.71% |
| Company Market Capitalisation | Rs 1,10,515.04 crore |
| Benchmark Median Market Cap | Rs 750.93 crore |
| Benchmark Average Market Cap | Rs 14,206.91 crore |
The sector data places Cipla in a large and valuation-diverse Pharmaceuticals & Drugs universe. Within the same industry benchmark of 200 companies, its valuation sits close to the median on both earnings and book value multiples, while ROCE is above the typical industry level.
In the same-industry benchmark, the P/E dataset covers 169 companies, with a median of 32.73, an average of 49.1, and a range from 3.4 to 701.57. Cipla’s P/E of 33.08 is slightly above the median but well below the average. Its P/B of 3.17 is also just above the median of 3.06 and below the average of 4.42.
On profitability, ROE matches the median exactly at 11.83% and is above the average of 11.22%, while ROCE of 16% is above both the median of 13.68% and the average of 13.71%. Market-cap data across 200 companies shows a median of Rs 750.93 crore and an average of Rs 14,206.91 crore, compared with Cipla’s Rs 1,10,515.04 crore. That confirms the company is much larger than the typical industry constituent.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,48,315.74 | 36.98 | 5.17 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,51,737.22 | 85.36 | 14.14 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,87,593.62 | 85.95 | 20.89 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,12,618.18 | 24.71 | 4.14 | 19.69 | 21.39 |
| Laurus Labs | LAURUSLABS | 1,04,455.86 | 95.67 | 18.55 | 18.31 | 18.2 |
Against major listed peers, Cipla appears moderate on valuation but less aggressive on profitability. Its P/E of 33.08 is below Sun Pharmaceutical Industries at 36.98, well below Divi’s Laboratories at 85.36, Torrent Pharmaceuticals at 85.95 and Laurus Labs at 95.67, but above Zydus Lifesciences at 24.71.
Market-cap comparison shows Cipla at Rs 1,10,515.04 crore, smaller than Sun Pharma, Divi’s and Torrent, but close to Zydus at Rs 1,12,618.18 crore and above Laurus Labs at Rs 1,04,455.86 crore.
On return ratios, Cipla’s ROE of 11.83% trails Sun Pharma’s 14.85%, Divi’s 16.19%, Torrent 26.76%, Zydus 19.69% and Laurus 18.31%. ROCE of 16% is also lower than Sun Pharma’s 19.11%, Divi’s 21.51%, Torrent 19.27%, Zydus 21.39% and Laurus 18.2%. Its P/B ratio of 3.17 is lower than all five peers listed in the table.
Why Investors Are Watching Cipla
- Today’s move: the stock fell 2.16% to Rs 1,350.25 from the previous close of Rs 1,380.
- Intraday structure: the stock opened at Rs 1,370.05, which was also the day’s high, and slipped near the low of Rs 1,348.95.
- Technical position: RSI at 36.94 points to weak momentum, while the price is below the 50 DMA of Rs 1,430.92 and the 200 DMA of Rs 1,381.51.
- Fundamental context: P/E is 33.08, P/B is 3.17, ROE is 11.83%, ROCE is 16%, EPS is Rs 41.72 and book value is Rs 435.18.
- Industry standing: Cipla is a Rs 1,10,515.04 crore Large Cap in Healthcare, with valuation near industry medians but return ratios below several key peers.
About Cipla
Cipla is part of the Healthcare sector and operates within the Pharmaceuticals & Drugs industry. Based on the supplied market data, it is one of the larger listed companies in its industry, with a market capitalisation of Rs 1,10,515.04 crore.
For investors following the company, the key verified context is that it sits in a large listed pharma universe where valuation multiples and return ratios vary sharply across peers. That makes the stock useful to track not only for daily price action, but also for relative valuation and industry positioning.
Track Cipla Share Price on Univest
UseCipla (CIPLA) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
On Univest, users can track Cipla Share Price through live market moves, valuation ratios, shareholding pattern updates when available, peer comparisons and broader market insights.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Cipla Share Price falling today?
Ans. Cipla Share Price was down 2.16% at Rs 1,350.25 versus the previous close of Rs 1,380. The supplied data confirms the decline and weak intraday price action, but it does not identify any company-specific catalyst for the move.
What is Cipla Share Price Today?
Ans. Cipla Share Price Today stood at Rs 1,350.25 at 9:52:59 AM IST on 11 September 2026. That was a fall of Rs 29.75, or 2.16%, from the previous close of Rs 1,380.
What does today’s price action show for Cipla?
Ans. The stock opened at Rs 1,370.05, which was also the day’s high, and later slipped to Rs 1,348.95. Staying below the previous close through the session points to a weak opening-to-low intraday structure.
Is Cipla a Large Cap stock?
Ans. Yes. Cipla is classified as a Large Cap company in the supplied data, with a market capitalisation of Rs 1,10,515.04 crore. That scale is well above the Pharmaceuticals & Drugs industry median market cap of Rs 750.93 crore.
What valuation ratios are investors tracking for Cipla?
Ans. Investors are tracking a P/E ratio of 33.08 and a P/B ratio of 3.17. Against the same-industry benchmark, the P/E is slightly above the median 32.73, while the P/B is modestly above the median 3.06.
How profitable is Cipla compared with its industry?
Ans. Cipla’s ROE is 11.83%, exactly matching the industry median and slightly above the 11.22% average. Its ROCE is 16%, which is stronger than both the industry median of 13.68% and average of 13.71%.
What do EPS, book value and dividend yield show for Cipla?
Ans. Cipla’s EPS is Rs 41.72, book value per share is Rs 435.18 and dividend yield is 0.94%. Together, these figures provide context on earnings, accounting net worth per share and historical payout relative to price.
How does Cipla compare with pharma peers on valuation?
Ans. Cipla’s P/E of 33.08 is below Sun Pharma’s 36.98 and far below Divi's, Torrent and Laurus Labs, which trade above 85. It is, however, above Zydus Lifesciences, which trades at a P/E of 24.71.
How does Cipla compare with peers on return ratios?
Ans. Cipla’s ROE of 11.83% and ROCE of 16% are lower than the figures shown for Sun Pharma, Divi's, Torrent, Zydus and Laurus Labs. That suggests a moderate profitability profile within this peer set.
What should investors monitor next in Cipla stock?
Ans. Investors may watch whether the stock stabilises above the day low of Rs 1,348.95, how it behaves relative to the 200 DMA of Rs 1,381.51 and 50 DMA of Rs 1,430.92, and whether valuation stays near industry norms.
